Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biocryst Pharmaceuticals Inc (BCRX)  
$6.28 0.19 (2.94%) as of 4:30 Fri 5/17


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 189,490,000
Market Cap: 1.19(B)
Last Volume: 4,378,853 Avg Vol: 4,460,019
52 Week Range: $4.13 - $8.81
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    : 14
Insider 6 Months    : 14
Insider 3/6 Months : 27.5
Guru Rank Number :  455
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioCryst Pharmaceuticals is a commercial-stage biotechnology company that discovers oral, small-molecule medicines. Co. focuses on oral treatments for rare diseases. Co.'s drug/drug candidates include: ORLADEYO™ (berotralstat), an oral serine protease inhibitor targeting kallikrein that is being developed for the prevention of Hereditary Angioedema attacks; BCX9930, an oral factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors for the treatment of fibrodysplasia ossificans progressive; and RAPIVAB® (peramivir injection), an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 153,240 153,240 153,240 153,240
Total Buy Value $856,692 $856,692 $856,692 $856,692
Total People Bought 6 6 6 6
Total Buy Transactions 6 6 6 6
Total Shares Sold 0 0 16,866 495,199
Total Sell Value $0 $0 $135,363 $5,999,241
Total People Sold 0 0 2 9
Total Sell Transactions 0 0 2 14
End Date 2024-02-18 2023-11-17 2023-05-19 2022-05-19

   
Records found: 475
  Page 15 of 19  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Hutson Nancy J Director   •       •      –    2016-12-01 4 A $5.59 $9,995 D/D 1,788 28,664     -
   Cohen Fred E Director   •       •      –    2016-12-01 4 A $5.59 $9,995 D/D 1,788 115,867     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2016-09-14 4 AS $4.27 $35,684 D/D (8,357) 79,377     -
   Ingram Robert Alexander Director   •       •      –    2016-09-01 4 A $4.11 $10,000 D/D 2,433 2,433     -
   Hutson Nancy J Director   •       •      –    2016-09-01 4 A $4.11 $10,000 D/D 2,433 26,876     -
   Cohen Fred E Director   •       •      –    2016-09-01 4 A $4.11 $10,000 D/D 2,433 114,079     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2016-08-25 4 S $4.06 $121,800 D/D (30,000) 111,428     -
   Baker Felix 10% Owner   –       –       •   2016-08-16 4 S $4.29 $4,246 I/I (990) 9,418,390     -
   Baker Felix 10% Owner   –       –       •   2016-08-15 4 S $4.83 $1,931,040 I/I (400,000) 9,419,240     -
   Baker Felix 10% Owner   –       –       •   2016-08-12 4 S $5.00 $18,315,817 I/I (3,645,600) 9,762,823     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2016-08-12 4 S $5.22 $23,793 D/D (4,558) 124,187     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2016-08-11 4 S $5.05 $6,595 D/D (1,306) 128,745     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2016-08-09 4 S $4.43 $64,576 D/D (14,577) 130,051     -
   Hutson Nancy J Director   •       •      –    2016-05-31 4 A $3.39 $8,750 D/D 2,581 24,443     -
   Cohen Fred E Director   •       •      –    2016-05-31 4 A $3.39 $8,750 D/D 2,581 111,646     -
   Barnes Alane P VP, General Counsel & Corp Sec   •       •      –    2016-03-01 4 D $2.13 $1,463 D/D (687) 85,416     -
   Babu Yarlagadda S Senior VP - Drug Discovery   •       •      –    2016-03-01 4 D $2.13 $1,930 D/D (906) 141,428     -
   Sheridan William P Senior VP - CMO   •       •      –    2016-03-01 4 D $2.13 $1,702 D/D (799) 90,052     -
   Staab Thomas R Ii Senior Vice President and CFO   •       •      –    2016-03-01 4 D $2.13 $990 D/D (465) 144,628     -
   Stonehouse Jon P President & CEO   •       •      –    2016-03-01 4 D $2.13 $5,881 D/D (2,761) 664,585     -
   Cohen Fred E Director   •       •      –    2016-02-29 4 A $1.99 $8,748 D/D 4,396 109,065     -
   Sanders Charles A Director   •       •      –    2016-02-29 4 A $1.99 $8,748 D/D 4,396 12,971     -
   Hutson Nancy J Director   •       •      –    2016-02-29 4 A $1.99 $8,748 D/D 4,396 21,862     -
   Baker Felix 10% Owner   –       –       •   2016-02-05 4 B $6.33 $284,657 I/I 45,000 12,894,240 1.5     -
   Baker Felix 10% Owner   –       –       •   2016-02-04 4 B $6.65 $164,915 I/I 24,800 12,849,240 1.5     -
  475 Records found
  Previous  10  11  12  13  14  15  16  17  18  19   
  Page 15 of 19
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us